Skip to main content
    M

    MEDIFAST INC (MED)

    Official site

    CONSUMER CYCLICAL • PERSONAL SERVICES • NYSE

    $12.52
    -0.45 (-3.47%)

    Market Cap: $145.04M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MEDIFAST INC (MED) Earnings: Report Dates and Results

    Updated Oct 26, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    MEDIFAST INC (MED) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, MEDIFAST INC reported EPS of -$0.19, above the -$0.40 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    83%(33/40)
    Avg Surprise
    +29.62%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.01
    Range$0.01 - $0.01
    2 analysts
    Revenue Consensus
    $64.03M
    Range$62.13M - $66.57M
    2 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.06
    Range-$0.06 - -$0.06
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.24+75.0%
    60d ago-$0.15+60.0%
    30d ago-$0.15+60.0%
    7d ago-$0.15+60.0%
    Current-$0.06
    Revenue Consensus
    $70.10M
    Range$70.10M - $70.10M
    1 analysts

    Next Report

    MED has an expected report date of Feb 15, 2027.

    MED Earnings Call

    The latest MED earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, MED beat 33, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $72.05M, down 19.4% from $89.41M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.19-$0.40N/A+52.50%BeatN/A11 up, 0 downOct 26, 2026$72.05M
    Jun 30, 2026-$0.28-$0.67N/A+58.21%Beat-227.3%10 up, 1 downAug 3, 2026$76.38M
    Mar 31, 2026-$0.19-$0.52-$0.52 - -$0.52+63.46%BeatN/A10 up, 1 downMay 4, 2026$76.04M
    Dec 31, 2025-$1.65-$0.45N/A-266.67%Miss-1750.0%11 up, 0 downFeb 17, 2026$75.10M
    Sep 30, 2025-$0.21-$0.36-$0.36 - -$0.36+41.67%Beat-160.0%11 up, 0 downNov 3, 2025$89.41M
    Jun 30, 2025$0.22-$0.19-$0.19 - -$0.19+215.79%Beat-76.1%10 up, 1 downAug 4, 2025$105.56M
    Mar 31, 2025-$0.07-$0.25-$0.25 - -$0.25+72.00%Beat-110.6%10 up, 1 downApr 28, 2025$115.73M
    Dec 31, 2024$0.10$0.24N/A-58.75%Miss-81.8%22 up, 0 downFeb 18, 2025$119.00M
    Sep 30, 2024$0.35-$0.28-$0.40 - -$0.15+225.00%Beat-83.5%20 up, 0 downNov 4, 2024$140.16M
    Jun 30, 2024$0.92$0.39$0.38 - $0.40+135.90%Beat-66.8%21 up, 0 downAug 5, 2024$168.56M
    Mar 31, 2024$0.66$0.80$0.74 - $0.82-17.50%Miss-82.0%20 up, 0 downApr 29, 2024$174.74M
    Dec 31, 2023$0.55$0.96$0.93 - $0.99-42.71%Miss-83.2%21 up, 0 downFeb 20, 2024$191.01M
    Sep 30, 2023$2.12$1.07$1.02 - $1.11+98.13%Beat-36.1%20 up, 0 downNov 6, 2023$235.87M
    Jun 30, 2023$2.77$1.44$1.44 - $1.44+92.36%Beat-28.4%10 up, 0 downAug 7, 2023$296.19M
    Mar 31, 2023$3.67$2.40$2.40 - $2.40+52.92%Beat+2.2%10 up, 0 downMay 1, 2023$348.98M
    Dec 31, 2022$3.27$2.22$2.22 - $2.22+47.30%Beat+12.4%10 up, 0 downFeb 21, 2023$337.25M
    Sep 30, 2022$3.32$1.91$1.91 - $1.91+73.82%Beat-6.7%10 up, 0 downNov 3, 2022$390.40M
    Jun 30, 2022$3.87$3.23$2.98 - $3.57+19.81%Beat-2.3%30 up, 1 downAug 3, 2022$453.33M
    Mar 31, 2022$3.59$3.57$3.43 - $3.68+0.56%Beat+3.8%31 up, 0 downMay 2, 2022$417.60M
    Dec 31, 2021$2.91$2.65$2.62 - $2.68+9.81%Beat+23.3%3N/AFeb 23, 2022$377.83M
    Sep 30, 2021$3.56$2.92$2.42 - $3.42+21.92%Beat+22.3%30 up, 0 downNov 4, 2021$413.39M
    Jun 30, 2021$3.96$3.30$3.06 - $3.54+20.00%Beat+102.0%3N/AAug 4, 2021$394.19M
    Mar 31, 2021$3.46$2.72$2.61 - $2.89+27.21%Beat+79.3%4N/AMay 4, 2021$340.67M
    Dec 31, 2020$2.36$2.38$2.20 - $2.60-0.84%Miss+42.2%5N/AFeb 25, 2021$264.91M
    Sep 30, 2020$2.91$2.49$2.31 - $2.74+16.87%Beat+120.5%4N/ANov 2, 2020$271.47M
    Jun 30, 2020$1.96$1.84$1.80 - $1.89+6.52%Beat+12.0%4N/AAug 5, 2020$220.00M
    Mar 31, 2020$1.93$1.33$1.21 - $1.42+45.11%Beat+13.5%3N/AMay 5, 2020$178.46M
    Dec 31, 2019$1.66$1.08$1.06 - $1.10+53.70%Beat+27.7%4N/AFeb 26, 2020$170.63M
    Sep 30, 2019$1.32$1.33$1.32 - $1.35-0.75%Miss+15.8%4N/ANov 7, 2019$190.06M
    Jun 30, 2019$1.75$1.72$1.70 - $1.74+1.74%Beat+50.9%4N/AAug 1, 2019$187.10M
    Mar 31, 2019$1.70$1.53$1.52 - $1.55+11.11%Beat+68.3%3N/AMay 1, 2019$165.88M
    Dec 31, 2018$1.30$1.21$1.19 - $1.24+7.44%Beat+116.7%3N/AFeb 26, 2019$145.84M
    Sep 30, 2018$1.14$1.14$1.13 - $1.150.00%In line+107.3%3N/ANov 6, 2018$139.24M
    Jun 30, 2018$1.16$0.98$0.96 - $1.05+18.37%Beat+84.1%3N/AAug 2, 2018$117.32M
    Mar 31, 2018$1.01$0.86$0.86 - $0.87+17.44%Beat+98.0%3N/AMay 3, 2018$98.60M
    Dec 31, 2017$0.60$0.48$0.48 - $0.48+25.00%Beat+76.5%3N/AMar 6, 2018$78.01M
    Sep 30, 2017$0.55$0.51$0.51 - $0.51+7.84%Beat+7.8%2N/ANov 7, 2017$77.20M
    Jun 30, 2017$0.63$0.52$0.52 - $0.52+21.15%Beat0.0%1N/AAug 8, 2017$75.73M
    Mar 31, 2017$0.51$0.47N/A+8.51%Beat+21.4%N/AN/AMay 4, 2017$70.62M
    Dec 31, 2016$0.34$0.33N/A+3.03%Beat+3.0%N/AN/AMar 9, 2017$62.47M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.71, after $2.03 the year before. It was $1.90 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.71-184.2%
    Dec 31, 2024$2.03-77.7%
    Dec 31, 2023$9.11-35.2%
    Dec 31, 2022$14.05+1.2%
    Dec 31, 2021$13.89+51.6%
    Dec 31, 2020$9.16+42.5%
    Dec 31, 2019$6.43+39.5%
    Dec 31, 2018$4.61+101.3%
    Dec 31, 2017$2.29+20.5%
    Dec 31, 2016$1.90N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,900 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,8665
    2026Q2Jun 30, 20264,2115
    2026Q1Mar 31, 20265,2067
    2025Q4Dec 31, 20254,4066
    2025Q3Sep 30, 20254,2046
    2025Q2Jun 30, 20253,6276
    2025Q1Mar 31, 20255,0107
    2024Q4Dec 31, 20245,5796

    2026Q3 Earnings Call

    Opening remarks

    Steven Zenker Manager of Investor Relations Good morning, and welcome to Medifast's third quarter 2026 Earnings Conference Call. On the call with me today are Nicholas Johnson, Chief Executive Officer, and James Maloney, Chief Financial Officer. By now, everyone should have access to the earnings release for the third quarter ended September 30, 2026, which went out this morning at approximately 8:05 a.m. Eastern Time. If you have not received the release, it is available on the investor relations portion of Medifast's website at www.medifastinc.com. This call is being webcast, and a replay will also be available on the company's website. Before we begin, we would like to remind everyone that today's prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. The words believe, expect, anticipate, and other similar expressions generally identify forward-looking statements. These statements do not guarantee future performance and, therefore, undue reliance should not be placed on them. Actual results could differ materially from those projected in any forward-looking statements. All of the forward-looking statements contained herein speak only as of the date of this call. Medifast assumes no obligation to update any forward-looking statements that may be made in today's release or call. Now I would like to turn the call over to Medifast's Chief Executive Officer, Nicholas Johnson.

    Nicholas Johnson Chief Executive Officer Thanks, Steven, and good morning, everyone. Thanks for joining us on the call today and for your continued interest in Medifast. Our third quarter was all about execution. With our new brand, Trilogy, now live, new products available, and an enhanced compensation plan and unified coach training platform launched, our 3.0 business is rolling out. Early results are already showing up in the field. We delivered revenue in line with guidance at $72 million, continuing the trend of stabilizing revenue around $75 million for the fourth consecutive quarter. Coach productivity continues to improve. We believe these trends leave us well positioned to deliver profitability in the fourth quarter. We ended the quarter with $173 million in cash and investments and no debt. Our enterprise value continues to sit below the value of our cash and investments. A debt-free balance sheet and a leaner cost structure give us a stable base from which to grow and invest in initiatives that can help deliver scale and profitability. Trilogy is differentiating Medifast in a large and growing metabolic health market, a market that we believe our coaches are well positioned to own. Over the past few months, we launched the Medifast Metabolic Health Institute, introduced our MetaVantage technology ingredient platform, and brought new products and training to market that are designed to give us a solid foundation to deliver for clients in the metabolic health category.

    Frequently Asked Questions About MED

    When is MEDIFAST INC's next earnings date?

    MEDIFAST INC's next earnings report is expected for Feb 15, 2027.

    Did MED beat earnings estimates last quarter?

    Yes. MEDIFAST INC reported EPS of -$0.19 for the quarter ended Sep 30, 2026, above the -$0.40 estimate, a 52.50% surprise.

    What EPS do analysts expect from MED next quarter?

    The consensus EPS estimate for MEDIFAST INC for the quarter ending Dec 31, 2026 is $0.01 from 2 analysts, with estimates from $0.01 to $0.01.

    How often does MED beat earnings estimates?

    MEDIFAST INC beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +22.28%.